Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

Two novel oral drugs that target androgen signaling have recently become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate inhibits the synthesis of the natural ligands of the androgen receptor, whereas enzalutamide directly inhibits the andr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacokinet
Autores principales: Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2016
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5069300/
https://ncbi.nlm.nih.gov/pubmed/27106175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-016-0403-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares